KPTI Earnings

Quarterly EPS
$-3.85
Q3 2024
$-3.67
Q4 2024
$-2.77
Q1 2025
$-4.32
Q2 2025
$-3.82
Q3 2025
$-5.68
Q4 2025
$-1.02
Q1 2026
$-2.32
Q2 2026
Latest Revenue33.4M
Latest Net Income-67023000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$2.3233.4M-67023000-11.9%+46.3%
Q1 2026-$1.0235.1M-22392000+16.8%+63.2%
Q4 2025-$5.6834.1M-102198000+11.6%-54.8%
Q3 2025-$3.8244.0M-33127000+13.6%+0.8%
Q2 2025-$4.3237.9M-37252000-11.4%-291.2%
Q1 2025-$2.7730.0M-23462000-9.4%+42.9%
Q4 2024-$3.6730.5M-30780000-9.5%+32.9%
Q3 2024-$3.8538.8M-32072000+7.7%+14.4%
Q2 2024$2.2642.8M23.8M
Q1 2024-$4.8533.1M-37362000
Q4 2023-$5.4733.7M-41837000
Q3 2023-$4.5036.0M-34506000
Karyopharm Therapeutics (KPTI) — Earnings